Home > News > Canada: Pharma In Brief - Canada: Changes In Quebec Pharmaceutical Reimbursement Policy

News

Canada: Pharma In Brief - Canada: Changes In Quebec Pharmaceutical Reimbursement Policy
2013-09-09 05:33:50

The Quebec government recently announced, as part of its budget, the intended abolishment of the rule known as "BAP-15." Under the BAP-15 policy, which has been in place since 1994, the Quebec government would pay the cost of the brand for 15 years for publicly covered patients, even if a generic competitor entered onto the formulary before that time. Although the 15-year rule was put in place with the balancing "best available price rule" (meaning that the manufacturer's selling price for a covered product in the province of Quebec could be no more than the selling price under other provincial plans), so far there has been no formal announcement of any change to that aspect of the policy in Quebec. In other words, the most favoured nation type of policy for Quebec remains in place vis-à-vis pricing of products in other provinces.

The RAMQ has now issued an Infolettre, dated December 14, 2012, announcing that as of January 14, 2013, the 15-year rule in respect of multi-source products will be abolished, and that the mechanism of annual price increases has also been abolished. Accordingly to the Infolettre, the prices of all products on the Liste des medicaments will be maintained at their current level. It is, however, possible for a manufacturer to submit a lower price.

The RAMQ advisory, in French, may be found at: http://www.ramq.gouv.qc.ca/SiteCollectionDocuments/
professionnels/infolettres/2012/info229-2.pdf
.

The pricing and reimbursement landscape for pharmaceutical and biologic products in Canada is ever-changing. We will be monitoring developments in the Quebec market, with a view to reporting on updates as they arise.

Norton Rose Group

Norton Rose Group is a leading international legal practice. We offer a full business law service to many of the world's pre-eminent financial institutions and corporations from offices in Europe, Asia, Australia, Canada, Africa, the Middle East, Latin America and Central Asia.

Knowing how our clients' businesses work and understanding what drives their industries is fundamental to us. Our lawyers share industry knowledge and sector expertise across borders, enabling us to support our clients anywhere in the world. We are strong in financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and pharmaceuticals and life sciences.

We have more than 2900 lawyers operating from 43 offices in Abu Dhabi, Almaty, Amsterdam, Athens, Bahrain, Bangkok, Beijing, Bogotá, Brisbane, Brussels, Calgary, Canberra, Cape Town, Caracas, Casablanca, Dubai, Durban, Frankfurt, Hamburg, Hong Kong, Johannesburg, London, Melbourne, Milan, Montréal, Moscow, Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome, Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from associate offices in Dar es Salaam, Ho Chi Minh City and Jakarta.

Norton Rose Group comprises Norton Rose LLP, Norton Rose Australia, Norton Rose Canada LLP, Norton Rose South Africa (incorporated as Deneys Reitz Inc), and their respective affiliates.

On January 1, 2012, Macleod Dixon joined Norton Rose Group adding strength and depth in Canada, Latin America and around the world. For more information please visit nortonrose.com.


Previous   [Return Home] [Print] [Go Back]   Next